Nexalin Technology (NASDAQ:NXL – Get Free Report) is one of 76 publicly traded companies in the “Electromedical Devices” industry, but how does it stack up against its peers? Compare Nexalin Technology to similar companies based on the strength of revenue, institutional holdings, risk, valuation, dividends, analyst recommendations and profitability.
Analysts’ comments
Here’s a breakdown of recent valuations for Nexalin Technology and its peers, as reported by MarketBeat.
| Sell ​​rating | Ratings on hold | Purchase Rating | Strong Buy Rating | Evaluation score | |
| Nexalin Technology | 0 | 0 | 0 | 0 | N/A |
| Nexalin Technology Competitors | 252 | 769 | 2038 | 101 | 2.63 |
As a group, the “electrical medical devices” companies have an upside potential of 27.31%. Considering the higher upside potential of Nexalin Technology’s peers, analysts clearly believe that Nexalin Technology’s growth profile is weaker than its peers.
Revenue and Ratings
This table compares the total revenue, earnings per share, and valuation of Nexalin Technology and its competitors.
| Earnings | Net income | Price Earnings Ratio | |
| Nexalin Technology | $110,000.00 | -$4.65 million | -2.52 |
| Nexalin Technology Competitors | $986.96 million | $82.19 million | -8.53 |
Nexalin Technology’s peers have higher revenues and profits than Nexalin Technology. Nexalin Technology trades at a higher price-to-earnings multiple than its peers, indicating that it is currently more expensive than its peers.
Profitability
This table compares the net profit margin, return on equity, and return on assets of Nexalin Technology and its competitors.
| Net income | Return on Equity | Return on Assets | |
| Nexalin Technology | -3,088.12% | -154.84% | -122.94% |
| Nexalin Technology Competitors | -152.14% | -47.46% | -5.34% |
Risk and Volatility
Nexalin Technology’s beta is 5.53, meaning that the company’s share price is 453% more volatile than the S&P 500. In comparison, Nexalin Technology’s peer group beta is 12.70, meaning that the company’s average share price is 1,170% more volatile than the S&P 500.
Institutional and insider ownership
0.7% of Nexalin Technology’s shares are held by institutional investors. In comparison, 45.1% of shares in all “Electromedical Devices” companies are held by institutional investors. 27.7% of Nexalin Technology’s shares are held by insiders. In comparison, 14.8% of shares in all “Electromedical Devices” companies are held by insiders. Strong institutional ownership indicates that large asset managers, endowments, and hedge funds believe the stock is poised for long-term growth.
summary
Nexalin Technology’s peers outperformed Nexalin Technology on eight of the ten factors compared.
About Nexalin Technology
(Get your free report)
Nexalin Technology, Inc. is a medical device company that designs and develops neurostimulation products for mental health treatment in the United States and China. The company is designing and developing second and third generation devices in clinical trials for the treatment of substance abuse problems related to opiates, cocaine and alcohol abuse, Alzheimer’s disease and dementia. The company also licenses and sells non-invasive, undetectable Nexalin devices that can provide relief to people suffering from mental health issues. The company is based in Houston, Texas.
Receive daily news and reviews from Nexalin Technology –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Nexalin Technology and related companies every day with MarketBeat.com’s free email newsletter.
